← All trials
NCT05773846
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2023
- Primary completion
- Dec 30, 2023
- Completion date
- Jan 30, 2024
- First posted
- Mar 17, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 415
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PainReform LTDLead sponsor
- Lotus Clinical ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.